Trigeminal Nerve Stimulation an Option for ADHD?
May 20, 2013
Currently, the system has no approvals in the United States from the US Food and Drug Administration (FDA).
Leon Ekchian, president and CEO of NeuroSigma, Inc, said the company plans first to apply for the epilepsy indication in the United States, with depression next and ADHD indications probably further down the road.
EU Approval for Nerve Stimulator in Depression, Epilepsy
Emma Hitt, PhD
Sep 07, 2012
An external trigeminal nerve stimulation (eTNS) system (Monarch, NeuroSigma, Inc) has received European Union (EU) CE Certification for the adjunctive treatment of epilepsy and major depressive disorder for adults and children aged 9 years and older.
The device has been evaluated in clinical trials conducted at the University of California, Los Angeles (UCLA) and the University of Southern California. It consists of an external pulse generator and disposable electric patches placed on the forehead that are replaced daily and are worn primarily during sleep.